TITLE

FDA advisory panels call for clarification on duration of bisphosphonate use

AUTHOR(S)
Foster, Melissa
PUB. DATE
October 2011
SOURCE
Endocrine Today;Oct2011, Vol. 9 Issue 10, p1
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article reports that the Reproductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) has called for clarifications to the duration of use in bisphosphonate drug labeling.
ACCESSION #
67619211

 

Related Articles

  • New contraindication added to Reclast drug label.  // Reactions Weekly;9/10/2011, Issue 1368, p3 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) on August 30, 2011 to the drug label for Reclast (zoledronic acid), which caution its association with risks of renal failure in patients with a history of, or risk factors for, renal impairment.

  • Bisphosphonate label should indicate how long to take the drug, say FDA panels.  // Contemporary OB/GYN;Oct2011, Vol. 56 Issue 10, p19 

    The article reports that the FDA panel has stated that the labeling of bisphosphonates for the treatment of osteoporosis should include more specific information as how long women should use the drug.

  • FDA actions.  // Infectious Disease Alert;Dec2010 Pharmacology Watch, p2 

    This section offers news briefs concerning the measures taken by the U.S. Food and Drug Administration (FDA). The agency has approved fingolimod, a spingosine 1-phosphate receptor modulator, for treatment of relapsing types of multiple sclerosis. In March 2010, the agency ordered the revision of...

  • FDA actions. Elliott, William T. // Primary Care Reports;Dec2010 Pharmacology, p2 

    This section offers news briefs on actions taken by the U.S. Food and Drug Administration (FDA) as of December 2010. The FDA has approved fingolimod, an oral drug for the treatment of relapsing forms of multiple sclerosis. The agency has also approved dabigatran, a drug for the prevention of...

  • FDA: Possible increased risk of thigh bone fracture with bisphosphonates Labeling change adds warning about possible risks of long-term use of osteoporosis drugs.  // Biomedical Market Newsletter;12/20/2010, p52 

    The article reports that the U.S. Food & Drug Administration (FDA) has warned patients and health care providers about the possible risk of atypical thigh bone (femoral) fracture in patients who take bisphosphonates. It is a class of drugs which is used to prevent and treat osteoporosis....

  • Possible Fracture Risk With Osteoporosis Drugs.  // Biomedical Market Newsletter;12/20/2010, p56 

    The article reports that the Food & Drug Administration (FDA) is warning about a possible risk of a rare type of thigh bone fracture in people who take drugs known as bisphosphonates to treat osteoporosis. FDA saw increasing cases of femoral fracture in patients taking these prescription...

  • FDA Drug Safety Communication: Safety update for osteoporosis drugs, bisphosphonates, and atypical fractures.  // Biomedical Market Newsletter;12/20/2010, p57 

    The article reports that the Food & Drug Administration (FDA) is warning about a possible risk of a rare type of thigh bone fracture in people who take bisphosphonates, a kind of drugs used for treating osteoporosis. FDA saw increasing cases of femoral fracture in patients taking these...

  • FDA Update.  // Oncology Nurse Advisor;Jul/Aug2011, Vol. 2 Issue 4, p14 

    No abstract available.

  • FDA Panels Call for Clarification on Duration of Bisphosphonate Use.  // O&P Business News;10/1/2011, Vol. 20 Issue 12, p40 

    The article reports that the U.S. Food and Drug Administration (FDA)'s Drug Safety and Risk Management Committee and Reproductive Health Drugs Advisory Committee have voted to add clarifications to biphosphonate labeling. The FDA reviewed data on biphosphonate after a March 2010 FDA Drug Safety...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics